Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Under our present experimental conditions, treatment response did not correlate with TP53 or hMLH1 status, but was associated with apoptosis-related genes, most notably BNIP3.Int.J.Cancer (Radiat.Oncol.Invest.)90, 175-185 (2000).
|
10993958 |
2000 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Under our present experimental conditions, treatment response did not correlate with TP53 or hMLH1 status, but was associated with apoptosis-related genes, most notably BNIP3.Int.J.Cancer (Radiat.Oncol.Invest.)90, 175-185 (2000).
|
10993958 |
2000 |
Liver carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Among these differentially-expressed genes, the galectin-3, serine/threonine kinase SGK, translation factor eIF-4A, -4B, -3, fibroblast growth factor receptor, and ribosomal protein L35A were up-regulated; the mRNAs of Nip3, decorin, and the insulin-like growth factor binding protein-3 were down-regulated in HCC.
|
12521301 |
2002 |
Liver carcinoma
|
0.070 |
AlteredExpression
|
disease |
LHGDN |
We found that the gene expression of BNIP3 was up-regulated while ZK1, RAD23B, and HSPD1 were down-regulated during early apoptosis of the hepatoma cell mediated by PRE.
|
12215374 |
2002 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The data show a correlation between high expression of BNip3 in the DCIS cells and a high-grade, necrotic lesion that is likely to be associated with invasive tumour.
|
14648660 |
2003 |
Noninfiltrating Intraductal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The data show a correlation between high expression of BNip3 in the DCIS cells and a high-grade, necrotic lesion that is likely to be associated with invasive tumour.
|
14648660 |
2003 |
Transient Ischemic Attack
|
0.200 |
Biomarker
|
disease |
RGD |
Nuclear localization of the hypoxia-regulated pro-apoptotic protein BNIP3 after global brain ischemia in the rat hippocampus.
|
14972662 |
2004 |
Pancreatic carcinoma
|
0.080 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of the BNIP3 promoter was observed in all BNIP3-negative pancreatic cancer cell lines and eight of 10 pancreatic adenocarcinoma samples.
|
15289340 |
2004 |
Malignant neoplasm of pancreas
|
0.070 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of the BNIP3 promoter was observed in all BNIP3-negative pancreatic cancer cell lines and eight of 10 pancreatic adenocarcinoma samples.
|
15289340 |
2004 |
Pancreatic Neoplasm
|
0.040 |
Biomarker
|
disease |
LHGDN |
Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer.
|
15289340 |
2004 |
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer.
|
15328198 |
2004 |
Lung Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer.
|
15328198 |
2004 |
Multiple Myeloma
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
Among primary tumours, methylation of BNIP3 was detected in five of 34 (15%) acute lymphocytic leukaemias, six of 35 (17%) acute myelogenous leukaemias and three of 14 (21%) multiple myelomas.
|
15756280 |
2005 |
Malignant neoplasm of stomach
|
0.310 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation of BNIP3 was also detected in 66% of primary colorectal and 49% of primary gastric cancers, but not in normal tissue samples collected from areas adjacent to the tumors.
|
15709167 |
2005 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Aberrant methylation of BNIP3 was also detected in 66% of primary colorectal and 49% of primary gastric cancers, but not in normal tissue samples collected from areas adjacent to the tumors.
|
15709167 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors).
|
15856026 |
2005 |
Pancreatic carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
|
15837765 |
2005 |
Pancreatic carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The expression of BNIP3 was restored by the methyltransferase inhibitor 5-aza-deoxycytidine (5-aza-dC), as was the hypoxia-mediated pancreatic cancer cell death.
|
15942716 |
2005 |
Pancreatic carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively.
|
15856026 |
2005 |
Malignant neoplasm of pancreas
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
|
15837765 |
2005 |
Malignant neoplasm of pancreas
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively.
|
15856026 |
2005 |
Malignant neoplasm of pancreas
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
The expression of BNIP3 was restored by the methyltransferase inhibitor 5-aza-deoxycytidine (5-aza-dC), as was the hypoxia-mediated pancreatic cancer cell death.
|
15942716 |
2005 |
Pancreatic Neoplasm
|
0.040 |
AlteredExpression
|
disease |
LHGDN |
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
|
15856026 |
2005 |
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In VHL-defective RCC cells, we demonstrate that the protumorigenic genes encoding cyclin D1, transforming growth factor alpha, and vascular endothelial growth factor respond specifically to HIF-2alpha and that the proapoptotic gene encoding BNip3 responds positively to HIF-1alpha and negatively to HIF-2alpha, indicating that HIF-1alpha and HIF-2alpha have contrasting properties in the biology of RCC.
|
15964822 |
2005 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In VHL-defective RCC cells, we demonstrate that the protumorigenic genes encoding cyclin D1, transforming growth factor alpha, and vascular endothelial growth factor respond specifically to HIF-2alpha and that the proapoptotic gene encoding BNip3 responds positively to HIF-1alpha and negatively to HIF-2alpha, indicating that HIF-1alpha and HIF-2alpha have contrasting properties in the biology of RCC.
|
15964822 |
2005 |